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Objective To compare the long-term effects of tocolysis with
nifedipine or atosiban on child outcome at age 2.5–5.5 years.
Design The APOSTEL III trial was a multicentre randomised
controlled trial that compared tocolysis with nifedipine or
atosiban in 503 women with threatened preterm birth. Neonatal
outcomes did not differ between both treatment arms, except for
a higher incidence of intubation in the atosiban group.
Methods Parents were asked to complete four questionnaires
regarding neurodevelopment, executive function, behaviour
problems and general health.
Main outcome measures The main long-term outcome measure
was a composite of abnormal development at the age of 2.5–
5.5 years.
Results Of the 426 women eligible for follow-up, 196 (46%)
parents returned the questionnaires for 115 children in the
nifedipine group and 110 children in the atosiban group.
Abnormal development occurred in 32 children (30%) in the
nifedipine group and in 38 children (38%) in the atosiban group
(OR 0.74, 95% CI 0.41–1.34). The separate outcomes for
neurodevelopment, executive function, behaviour and general
health showed no significant differences between the groups.
Sensitivity analysis for all children of the APOSTEL III trial,
including a comparison of deceased children, resulted in a higher
rate of healthy survival in the nifedipine group (64 versus 54%),
but there was no significant difference in the overall mortality rate
(5.4 versus 2.7%). There were no significant subgroup effects.
Conclusion Outcomes on broad child neurodevelopment,
executive function, behaviour and general health were comparable
in both groups. Neither nifedipine nor atosiban can be considered
as the preferred treatment for women with threatened preterm
birth.
Keywords Atosiban, behaviour, child, development, executive
function, follow-up, health, infant, neurodevelopment, nifedipine,
preterm birth, preterm labour, tocolysis.
Tweetable abstract Nifedipine- and atosiban-exposed children had
comparable long-term outcomes, including neurodevelopment,
executive function and behaviour.
Linked article This article is commented on by JG Thornton,
p. 1138 in this issue. To view this mini commentary visit https://
doi.org/10.1111/1471-0528.16230.
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General obstetrics
Introduction
The effect of prenatal interventions, such as the use of
tocolytics, on long-term morbidity is largely unknown as
follow-up data, especially for older children, are scarce.1
Ultimately, the aim of treatment for threatened preterm
birth should not be to increase gestational age at the time
of birth, but to improve neonatal survival and healthy
development.
It is therefore crucial to assess long-term outcomes,
because even if a randomised controlled trial (RCT) shows
no difference between interventions on short-term out-
comes, the long-term development of the children may still
be affected. In the ORACLE II trial, in which antibiotic
therapy was compared with placebo for threatened preterm
labour with intact membranes, short-term outcomes were
similar between groups.2 At the 7-year follow-up, however,
a significant increase in functional impairment and cerebral
palsy was found in the group given antibiotics.3
The effect of two frequently used tocolytics, i.e. nifedip-
ine and atosiban, on the long-term health and development
of children is largely unknown. Long-term effects of
nifedipine have only been investigated in three smaller
studies.4-6 Only one retrospective cohort study on the long-
term effects of atosiban has been published, but this study
was limited to autism spectrum disorders in children
exposed to nifedipine alone or to nifedipine and atosiban
in combination.7
The APOSTEL III study was a multicentre randomised
trial that compared neonatal outcomes of tocolysis with
nifedipine or atosiban in threatened preterm birth.8,9 The
primary outcome, a composite of neonatal morbidity and
mortality, was comparable between the two arms (14% in
the nifedipine group and 15% in the atosiban group, RR
0.91, 95% CI 0.61–1.37), although a non-significant higher
mortality rate was observed in the nifedipine group (5.4%
in the nifedipine group and 2.4% in the atosiban group,
RR 2.20, 95% CI 0.91–5.33).
The aim of this study was to determine the long-term
effects of tocolysis with nifedipine or atosiban during
threatened preterm birth on neurodevelopment, executive
function, behavioural problems and the general health of
children.
Methods
Trial design and participants
The APOSTEL III study was a multicentre randomised
controlled trial that analysed 503 women with threatened
preterm birth and gestational age between 25+0 and
34+0 weeks of gestation, who were randomised to treatment
with nifedipine (n = 248) or atosiban (n = 255). Both sin-
gleton and twin pregnancies were included.
The sample size of this follow-up study was predefined
by the number of participants of the APOSTEL III trial. In
total, 503 mothers gave birth to 591 children (n = 297 trea-
ted with nifedipine and n = 294 treated with atosiban).
There were 23 perinatal deaths: 16 in the nifedipine group
and seven in the atosiban group.
In the design phase of the study, two patient organisa-
tions supported the study, and participated in the applica-
tion for funding. Both Vereniging van Ouders van
Couveusekinderen (VOC, a patient organisation for parents
of children that were admitted to the neonatal intensive
care unit) and Nederlandse Vereniging voor Ouders van
Meerlingen (NVOM, the Dutch society of parents of multi-
ples) were involved.
At the time that we applied for the funding of the fol-
low-up study, the methods were composed to the best of
our knowledge at that moment. Before the actual analyses
were performed, however, a number of changes were made
in consultation with methodologists and experts. Those
changes are marked and explained point by point in
Appendix S1.
Five years after the start of the original trial, we asked all
participants with a surviving child for written informed
consent to send four questionnaires. Women with children
older than 66 months were excluded, as the Ages & Stages
Questionnaires, Third Edition (ASQ-3TM) is not validated
above that age. Data on mortality after finalisation of the
RCT was gathered for all contactable participants.
Questionnaires
Four parent-reported questionnaires were used, three of
which are validated developmental questionnaires and one
is aimed at gathering data about general health and health-
care use.
ASQ-3 – neurodevelopment
The ASQ-3 questionnaire is used as a screening tool for
delay in six domains of development.10 Scores were com-
pared with a reference score file validated for the Dutch
population.11 A questionnaire was marked abnormal if the
score in at least one developmental field was ≥2 SD below
the mean.10
BRIEF-P – executive function
The Behaviour Rating Inventory of Executive Function –
Preschool (BRIEF-P) is a standardised questionnaire to
assess executive function, i.e. cognitive development and
attention, in children aged between 2 and 5 years.12 The
separate items describe different behavioural areas of execu-
tive functioning that together form the total score. Raw
scores were converted into T-scores and percentiles to cor-
rect for age and sex. Mean scores were compared with a
norm score file validated for the Dutch population. A T-
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score of 65 or higher (equivalent to 1.5 SD above the
mean) on the scales, indices and total score was considered
abnormal.13
CBCL – behaviour
The Child Behaviour Check List (CBCL) questionnaire
records behaviour and emotion in children aged between
1.5 and 5 years.14 The questions can be grouped into syn-
drome scales that inform on internalising and externalising
behaviour. The syndrome scales form a total problem
score. Scores were compared with the publisher’s reference
file.15 T-scores and percentiles were calculated. A T-score
of 64 or higher was considered abnormal.14
General health
Data regarding medical history – i.e. hospital admissions;
surgeries; visits to a general practitioner, medical specialist
or developmental specialist; and past and present medica-
tion use – were collected.
Outcome measures
The main outcome was a composite of abnormal develop-
ment at the age of 2.5–5.5 years. The proportion of chil-
dren with abnormal scores on at least one of the
development questionnaires and their subscales was com-
pared between the nifedipine and atosiban groups. Second-
ary outcomes included general health outcomes, as
described above.
Statistical analysis
For participants of follow-up, we compared characteristics
and outcomes between the nifedipine group and the atosi-
ban group. The Mann–Whitney U-test for continuous data,
Fisher’s exact test for dichotomous data and v2 test for cat-
egorical data were used, as appropriate.
For outcomes on the neonatal or child level, we
accounted for interdependence between outcomes of babies
from the same mother in multiple pregnancies.16,17 We
assessed binary outcomes with a generalised estimating
equations (GEE) model for binomial data with an unstruc-
tured correlation matrix, considering the mother as a clus-
ter variable. Odds ratios (ORs), 95% confidence intervals
(95% CIs) and P values are reported.
Likewise, we evaluated continuous outcomes on the
neonatal or child level with linear quantile mixed models
with the mother as a grouping variable, resulting in a med-
ian difference with 95% CI.18 All long-term child outcome
analyses were adjusted for gestational age at birth.
We examined possible subgroup effects for women with
and without intact membranes, singleton and multiple
pregnancies, gestational age at delivery <32+0 versus
≥32+0 weeks of gestation and <35+0 versus ≥35+0 weeks of
gestation. Subgroup effects were studied by including an
interaction term between the subgrouping variable and
treatment allocation in the regression model and were
adjusted for gestational age at birth.
We performed a sensitivity analysis in which we included
all children of the original APOSTEL III trial (n = 591).
For all children who did not participate in the follow-up,
outcomes were estimated based on the results (rates of
healthy survival and abnormal questionnaire score) of chil-
dren who did participate, stratified for singleton and multi-
ple pregnancies, and taking any deaths after the original
trial into account.
We compared rates of healthy survival, i.e. all normal
questionnaire scores and survival until the end of the fol-
low-up period, and all mortality between the nifedipine
and atosiban group.
Data preparation and statistical analyses were performed
using SPSS 25.0 (IBM Corp, Armonk, NY, USA) and R 3.5.1
(R Core Team, Vienna, Austria).
Results
Study population
Out of 486 women and 568 surviving children, 426 women
were eligible for follow-up and 281 (66%) agreed to partic-
ipate. Eventually, 196 (46%) of the eligible families
returned the questionnaires, encompassing data for 115
infants randomised to the nifedipine group (51%) and 110
infants randomised to the atosiban group (49%), 33 (29%)
and 26 (24%) of whom, respectively, were from a twin
pregnancy (Figure 1). The median age of the children at
the time of follow-up was 53 months (interquartile range
46–57 months), with a slightly higher percentage of boys
(58%). No differences were seen in these characteristics
between both groups (Table S1).
Baseline maternal characteristics did not differ between
both treatment arms in the participating group (Table 1).
Short-term neonatal outcomes for children up to a cor-
rected age of 3 months in this follow-up study showed a
higher incidence of intubation in the atosiban group,
whereas the median ventilation duration for nifedipine was
non-significantly longer (Table 2). Mothers in the partici-
pating group were older and were more often white, highly
educated and nulliparous, compared with mothers in the
non-participating group (Table S2). There were no differ-
ences in short-term neonatal outcomes when comparing
children who did and did not participate in the follow-up
(Table S3).
Main outcome
Developmental questionnaires
We received and included 225 ASQ-3 questionnaires. We
excluded any subscales that were filled in erroneously.10 In
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the BRIEF-P analysis, 11 completed questionnaires were
discarded for inconsistent and/or high negativity score (i.e.
negative bias of the parent) and two questionnaires because
of too many missing items. Ten CBCL questionnaires had
too many missing items and were therefore excluded from
the analysis. Developmental outcomes are shown in
Table 3.
Neurodevelopmental delay (ASQ-3) did not differ
between the nifedipine and atosiban groups (25 versus 28%
abnormal score, OR 0.92, 95% CI 0.50–1.71).
Executive function disorders (BRIEF-P) were also similar
in both groups (8.3 versus 9.8% abnormal score, OR 0.81,
95% CI 0.32–2.04). Behavioural problems (CBCL) were
also comparable between the nifedipine and atosiban
groups (9.0 versus 6.7% abnormal score, OR 1.32, 95% CI
0.47–3.72). Summarising the outcomes of the ASQ-3,
BRIEF-P and CBCL questionnaires, there were no signifi-
cant differences between the nifedipine and atosiban
exposed groups (30 versus 38% with any abnormal ques-
tionnaire score, OR 0.74, 95% CI 0.41–1.34). Only for the
ASQ-3 problem-solving scale was there a significantly lower
incidence of abnormal scores in the nifedipine group (4.4
versus 12.0%, OR 0.34, 95% CI 0.12–0.99).
General health questionnaire
No differences in general health were found between the
nifedipine and atosiban groups with respect to hospital
admissions, surgery, specialist visits (divided into general
practitioner, developmental specialist and medical special-
ist) and medication use. Given that no differences were
found for different subtypes (e.g. antibiotics or anti-epilep-
tics), we only reported on total medication use (Table 4).
Subgroup analysis
There were no significant interactions (P < 0.05) between
treatment allocation and subgroups of women with and
without intact membranes, singleton and multiple pregnan-
cies, gestational age at delivery <32+0 versus ≥32+0 weeks of
gestation and <35+0 versus ≥35+0 weeks of gestation
(Table S4).
Sensitivity analysis
A total of 24 children died during the study: 23 in the peri-
natal period and one during follow-up. In a sensitivity
analysis, the overall neonatal and childhood mortality from
randomisation until follow-up was 16/297 in the nifedipine
group and 8/294 in the atosiban group (5.4 versus 2.7%,
510 women randomised
254 nifedipine
5 withdrew consent 1 lost to follow-up
248 women analysed
297 children 
analysed
53 children excluded
36: child > 66 months
16: perinatal death
1: maternal psych. disorder
206 women
244 children eligible
107 women lost to 
follow-up
81: no response
17: refusal
5: emigraon
4: no address
99 women completed 
quesonnaires 
encompassing data of 
115 children (33 part of 
twin)
256 atosiban
0 withdrew consent 1 lost to follow-up
255 women analysed
294 children 
analysed
45 children excluded
36: child > 66 months
7: perinatal death
1: deceased during FU
1: maternal psych. disorder
220 women
249 children eligible
123 women lost to 
follow-up
100: no response
15: refusal
5: emigraon
3: no address
97 women completed 
quesonnaires 
encompassing data of 
110 children (26 part of 
twin)
Figure 1. CONSORT flow diagram of the APOSTEL III trial and its follow-up.19 , APOSTEL III RCT; , APOSTEL III Follow-up.
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OR 2.06, 95% CI 0.86–4.95). There were 190/297 healthy
survivors in the nifedipine group versus 159/294 healthy
survivors in the atosiban group (64 versus 54%, OR 1.50,
95% CI 1.06–2.12), and there were 91/297 children with
any abnormal questionnaire score in the nifedipine group
versus 127/294 children in the atosiban group (31 versus
43%, OR 0.58, 95% CI 0.41–0.83).
Discussion
Main findings
In this long-term follow-up study, we found comparable
outcomes in children exposed in utero to nifedipine or
atosiban in the composite broad developmental scores, as
well as in individual neurodevelopmental, executive func-
tional, behavioural and health outcomes. We did find a sig-
nificant difference in the ASQ-3 problem-solving scale in
favour of nifedipine. No additional interactions could be
found between treatment allocation and subgroups with
respect to intact or ruptured membranes, singleton and
multiple pregnancies and gestational age at delivery.
Strengths and limitations
There are several strengths of this study. First, this is the
first published follow-up study of an RCT describing the
Table 1. Baseline maternal characteristics according to treatment
arm
Nifedipine
(n = 99)
Atosiban
(n = 97)
P
Age (years) 31.1
(28.3–34.2)
30.6
(27.9–33.1)
0.34
Body mass index
(kg/m2)a
23.6
(21.5–26.0)
23.1
(21.2–25.7)
0.66
Whiteb 82 (89%) 82 (89%) 1.00
Educational levelc
Primary school 1 (2.6%) 2 (5.4%) 0.51
Secondary school 0 (0.0%) 0 (0.0%)
Lower professional
education
2 (5.1%) 2 (5.4%)
Medium professional
education
13 (33%) 11 (30%)
Higher professional
education
18 (46%) 12 (32%)
University 5 (13%) 10 (27%)
Nulliparous 73 (74%) 75 (77%) 0.62
History of preterm birth 9 (9.1%) 8 (8.2%) 1.00
Gestational age at
randomisation
30.6
(28.5–32.6)
30.6
(28.4–31.9)
0.47
Multiple gestation 17 (17%) 13 (13%) 0.55
PPROM 38 (38%) 31 (32%) 0.37
Cervical length (mm)d 17.0 (9.0–22.2) 13.0 (7.0–17.5) 0.12
Dilatatione 1.0 (1.0–2.0) 1.0 (0.0–2.5) 0.48
Outcome data are n (%) or median (IQR).
aNifedipine, n = 82; atosiban, n = 83.
bNifedipine, n = 92; atosiban, n = 92.
cNifedipine, n = 39; atosiban, n = 37.
dNifedipine, n = 64; atosiban, n = 55.
eNifedipine, n = 46; atosiban, n = 51.
Table 2. Short-term neonatal outcomes of children participating in
the follow-up study9
Nifedipine
(n = 115)
Atosiban
(n = 110)
P
Gestational age at
birth
33+0 (30+3–35+2) 31+6 (29+4–34+5) 0.16
Gestational age at birth
<28 weeks 10 (8.7%) 13 (11%) 0.44
28–32 weeks 38 (33%) 42 (38%)
>32 weeks 67 (58%) 55 (50%)
Adverse perinatal
composite
outcomea
13 (11%) 15 (14%) 0.60
Bronchopulmonary
dysplasia
4 (3.5%) 7 (6.4%) 0.33
Culture-proven
sepsis
11 (9.6%) 8 (7.3%) 0.54
Intraventricular
haemorrhage
(grade ≥3)
2 (1.7%) 0 (0.0%) —
Periventricular
leukomalacia
(grade ≥2)
0 (0.0%) 1 (0.9%) —
Necrotising
enterocolitis
(stage ≥2)
4 (3.5%) 1 (0.9%) 0.22
NICU admissionb 66 (57%) 71 (65%) 0.26
Length (days)d 14.5 (6.0–38.5) 18.0 (7.0–43.5) 0.75
Intubationc 11 (9.6%) 24 (23%) 0.017
Length (days)d 6.0 (2.0–13.5) 2.5 (1.0–5.2) 0.082
Any hospital
admission
103 (90%) 102 (93%) 0.41
Days in hospital 32.0 (18.5–54.0) 34.0 (21.0–62.0) 0.85
Apnoea 8 (7.0%) 13 (12%) 0.12
Asphyxia 0 (0.0%) 1 (0.9%) —
Proven meningitis 2 (1.7%) 0 (0.0%) —
Birthweight (g) 1920 (1553–2629) 1805 (1368–2419) 0.15
Outcome data are n (%) or median (IQR). Data are reported until
the corrected age of 3 months.
aComposed of perinatal in-hospital mortality and the following
perinatal morbidities: bronchopulmonary dysplasia, culture-proven
sepsis, intraventricular haemorrhage higher than grade 2,
periventricular leukomalacia higher than grade 1 and necrotising
enterocolitis higher than Bell’s stage 1.
bNifedipine, n = 115; atosiban, n = 109.
cNifedipine, n = 114; atosiban, n = 106.
dOnly reported for neonates who were admitted to the neonatal
intensive care unit (NICU) or who underwent intubation.
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long-term effects of atosiban on children’s development.
This study contributes to the available knowledge about the
long-term effects of two widely used tocolytics.
Second, responses to the questionnaires were scrutinised
and were not used if there were any doubts about the
veracity of the responses.
Third, the response rate of 46% in our study is reason-
able, considering that follow-up studies in the same field
yielded similar rates,6,20,21 and the extensive effort leading
to this result.
Several limitations require comment. First, the sample
size was limited by the number of participants of the
APOSTEL III trial willing to participate in the follow-up.
To investigate the representativeness of the sample, baseline
maternal and short-term neonatal outcomes (i.e. up until
discharge) were compared between participants and non-
Table 3. Abnormal outcomes by treatment arm
Domain Nifedipine (n = 115) Atosiban (n = 110) OR 95% CI P
No. abnormal No. abnormal
Abnormal total score on any
questionnaire
ASQ and/or BRIEF-P and/or CBCL
abnormal score
32/107 (30%) 38/100 (38%) 0.71 0.39–1.29 0.26
Neurodevelopment: ASQ-3
abnormala
Communication scale 9/113 (8.0%) 9/107 (8.4%) 0.79 0.28–2.17 0.64
Gross motor scale 8/110 (7.3%) 7/106 (6.6%) 1.07 0.37–3.13 0.89
Fine motor scale 18/112 (16%) 14/106 (13%) 1.46 0.65–3.29 0.36
Problem solving scale 5/113 (4.4%) 13/107 (12%) 0.33 0.11–0.98 0.047
Personal social scale 10/113 (8.8%) 10/107 (9.3%) 0.98 0.37–2.57 0.97
Total neurodevelopmental delay 28/111 (25%) 30/107 (28%) 0.92 0.49–1.73 0.79
Executive function: BRIEF-P
abnormalb
Inhibitory self-control index: inhibit
and emotional control scales
9/108 (8.3%) 9/103 (8.7%) 0.94 0.36–2.47 0.90
Flexibility index: shift and emotional
control scales
10/108 (9.3%) 12/104 (12%) 0.73 0.30–1.77 0.48
Emergent metacognition index:
working memory and plan/organise
scale
6/108 (5.6%) 10/103 (9.7%) 0.66 0.23–1.94 0.45
Total executive function disorders 9/108 (8.3%) 10/102 (9.8%) 0.79 0.31–2.01 0.62
Behaviour: CBCL abnormalc Internalising scale 10/111 (9.0%) 7/104 (6.7%) 1.32 0.48–3.62 0.59
Externalising scale 9/111 (8.1%) 5/104 (4.8%) 1.67 0.55–5.08 0.36
Total behavioural problems 10/111 (9.0%) 7/104 (6.7%) 1.31 0.46–3.74 0.62
According to the respective manuals, the cut-off values for defining an abnormal score are:
aAt least one developmental field scoring ≥2 SD below the mean.
bT-score of 65 or higher.
cT-score of 64 or higher.
Table 4. General health outcomes
Nifedipine (n = 115) Atosiban (n = 110) OR 95% CI P
Hospital admissions (any) 61/108 (57%) 53/108 (49%) 1.45 0.84–2.51 0.18
Hospital admissions (≥3) 14/108 (13%) 6/108 (5.6%) 3.18 1.05–9.66 0.041
Surgery (any) 38/110 (35%) 38/109 (35%) 1.03 0.58–1.84 0.92
Surgery (≥3) 8/110 (7.3%) 6/109 (5.6%) 1.54 0.48–4.90 0.47
Any specialist visits 91/112 (81%) 84/108 (78%) 1.47 0.72–3.00 0.29
General practitioner 65/112 (58%) 64/107 (60%) 0.98 0.55–1.76 0.96
Developmental specialist 55/110 (50 %) 48/107 (50%) 1.41 0.78–2.55 0.26
Medical specialist 79/112 (71%) 70/108 (65%) 1.43 0.76–2.68 0.27
Medication use (ever) 84/110 (76%) 75/109 (69%) 1.55 0.80–3.00 0.19
Medication use (current) 26/110 (24%) 25/109 (23%) 1.06 0.55–2.04 0.85
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participants of the follow-up study. We found small differ-
ences in maternal baseline characteristics and short-term
neonatal outcomes between both groups. This is consistent
with the phenomenon that participants of follow-up
research are generally older, more often white, higher edu-
cated and nulliparous than non-participants.22
Second, because of the non-significantly higher mortality
rate in the nifedipine group of the APOSTEL III trial, there
is a risk of bias because deceased and very disabled infants
are not able to participate in the follow-up. We investi-
gated this in a sensitivity analysis encompassing all children
of the original trial, including cases of perinatal and child
mortality. This showed no significant differences in overall
mortality. For surviving children, the rate of healthy sur-
vival was significantly higher in the nifedipine group. This
can only be regarded as an exploratory analysis, however,
and the result should be interpreted with caution. Out-
comes of children who did not participate could only be
estimated based on those of children who did participate in
the follow-up, thereby assuming that these groups are simi-
lar, whereas it is more likely that they are not. When data
are not missing at random, as is probably the case in this
study according to the follow-up baseline characteristics, all
imputation techniques may lead to inappropriate conclu-
sions.
Third, the choice of measuring the outcome by using
questionnaires requires comment. Obviously, objective data
from a professional observer in addition to the use of par-
ent-reported questionnaire data would be preferable,
although with large numbers of children this is difficult
and costly. Bringing children in for testing would have no
doubt further dwindled the numbers recruited to the study
groups. The questionnaires that we used are regarded as
validated screening tools for broad developmental prob-
lems. Moreover, our aim was not to make exact clinical
diagnoses but purely to demonstrate a potential difference
between the groups.
Interpretation (in light of other evidence)
Long-term follow-up of children exposed to tocolytics is
scarce. Only 16% of the large perinatal RCTs, including
tocolysis studies, report a follow-up of children, whereas
the development of the child is, besides child mortality, the
most important outcome.23
We believe that for making a proper assessment of the
superiority of either tocolytic, one should consider both
short-term and long-term outcomes, and stress that long-
term follow-up should become standard practice in all
obstetric intervention trials.
The previous APOSTEL II follow-up study compared the
long-term outcomes of maintenance treatment with
nifedipine versus placebo, using the ASQ-3 questionnaire.6
Overall, nifedipine-exposed children scored more poorly on
the fine-motor scale, but did better on the problem-solving
scale. Two other studies compared the long-term outcome
of children exposed to ritodrine and nifedipine. No differ-
ences between the groups were found.4,5 This study, there-
fore, contributes important information on the broad
development of children exposed to tocolytics.
Clinically, preterm birth is strongly associated with long-
term developmental problems. In our study, the nifedipine
group had both a non-significant higher healthy survival
and a higher mortality rate. In vitro studies have demon-
strated a potential neuroprotective effect of nifedipine,
which could be a pathophysiological explanation for the
better scores on the problem-solving scale in the nifedipine
group.24 Atosiban could have had a direct effect on the
fetal brain, although only a small portion of the peptide
reaches the child’s brain after placental transfer.25
There were small differences in short-term neonatal out-
comes among follow-up participants, where atosiban-ex-
posed children more often required intubation and
nifedipine-exposed children had a non-significantly longer
duration of intubation.
Based on our study, there seems to be a trade-off in the
outcome. This can be taken into consideration when coun-
selling a patient, although there is no compelling evidence
to favour one tocolytic over the other.
Conclusion
The APOSTEL III RCT found no differences in adverse
perinatal outcomes in infants exposed to nifedipine or
atosiban, and neither did this follow-up study in long-term
outcomes. Based on this evidence, there is no preference
for either nifedipine or atosiban in threatened preterm
birth.
Disclosure of interests
BWM reports consultancy for ObsEva, Merck and Guerbet.
BWM is supported by a National Health and Medical
Research Council (NHMRC) Practitioner Fellowship
(GNT1082548). All other authors report no conflicts of
interest. Completed disclosure of interests forms are avail-
able to view online as supporting information.
Contribution to authorship
TMSW, CEK and CAN had full access to all of the data in
the study and take responsibility for the integrity of the
data and the accuracy of the data analysis. Study concept
and design: TMSW, MAO and BWM. Acquisition, analysis,
or interpretation of the data: TMSW, MAO, CEK, MAT,
CR, CAN, ALB, AGW-L, TJR, JH, BWM and EP. Drafting
the manuscript: TMSW, MAO and CR. Critical revision of
the manuscript for important intellectual content: JK, CEK,
MT, CAN, TAN, ALB, AGW-L, TJR, JH, BWM and EP.
1135ª 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists
Impact of nifedipine and atosiban on child outcome
Statistical analysis: TMSW, CEK, MAT and CAN. Study
supervision: MAO, CR and EP.
Details of ethics approval
The study was approved by the Research Ethics Committee
of the Amsterdam UMC (ref. HREC AMC W15_039, 11
February 2015), with the note that the Medical Research
Involving Human Subjects Act does not apply to this study
as no negative consequences for mother or child can be
expected by participating. Parents of all participating chil-
dren provided written informed consent.
Funding
This study was funded by ZonMw, the Netherlands Organi-
sation for Health Research and Development ‘Healthcare
Rational Medicine’ programme, project number 836041012.
The original APOSTEL III study was also financially sup-
ported by ZonMw under project number 836011005,
NTR2947. ZonMw had no role in the study design, collec-
tion, analysis and interpretation of the data, writing of the
report and decision to submit the article for publication.
Acknowledgements
We thank ZonMw, the Netherlands Organisation for
Health Research and Development, for enabling and sup-
porting clinical research. We thank the research nurses,
midwives and administrative assistants of our consortium,
and the nurses, midwives, residents and gynaecologists of
the participating centres for their help with participant
recruitment and data collection. We thank Dr C. van de
Beek for sharing her experience regarding long-term fol-
low-up in obstetric studies. We offer special thanks to Dr
Jannet J.H. Bakker for her willingness to assist with the
early phases of the study.
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the
article.
Table S1. Characteristics of children participating in the
follow-up study.
Table S2. Baseline maternal characteristics of participants
included in the follow-up versus those not included in the
follow-up.
Table S3. Short-term neonatal outcomes of participants
included in the follow-up versus those not included in the
follow-up.
Table S4. Subgroup analyses.
Appendix S1. Protocol showing changes made in consul-
tation with methodologists or expert co-authors before the
actual analyses were performed.&
References
1 Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller A-B,
et al. Born too soon: the global epidemiology of 15 million preterm
births. Reprod Health 2013;10 (Suppl 1):S2.
2 Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative
Group. Broad-spectrum antibiotics for spontaneous preterm labour:
the ORACLE II randomised trial. ORACLE Collaborative Group.
Lancet 2001;357:989–94.
3 Kenyon S, Pike K, Jones D, Brocklehurst P, Marlow N, Salt A, et al.
Childhood outcomes after prescription of antibiotics to pregnant
women with spontaneous preterm labour: 7-year follow-up of the
ORACLE II trial. Lancet 2008;372:1319–27.
4 Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, Van
HPH, Bleker OP, et al. Long-term follow up of children exposed in
utero to nifedipine or ritodrine for the management of preterm
labour. BJOG 2006;113:324–31.
5 Van De Water M, Van Kessel ET, De Kleine MJ, Oei SG. Tocolytic
effectiveness of nifedipine versus ritodrine and follow-up of
newborns: a randomised controlled trial. Acta Obstet Gynecol Scand
2008;87:340–5.
6 van Vliet EOG, Seinen L, Roos C, Schuit E, Scheepers HCJ,
Bloemenkamp KWM, et al. Maintenance tocolysis with nifedipine in
threatened preterm labour: 2-year follow up of the offspring in the
APOSTEL II trial. BJOG 2016;123:1107–14.
7 Friedlander E, Feldstein O, Mankuta D, Yaari M, Harel-Gadassi A,
Ebstein RP, et al. Social impairments among children perinatally
exposed to oxytocin or oxytocin receptor antagonist. Early Hum Dev
2017;106–107:13–8.
8 van Vliet EO, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W,
et al. Nifedipine versus atosiban in the treatment of threatened
preterm labour (assessment of perinatal outcome after specific
tocolysis in early labour: APOSTEL III-trial). BMC Pregnancy Childbirth
2014;14:93.
9 Van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok
M, et al. Nifedipine versus atosiban for threatened preterm birth
(APOSTEL III): a multicentre, randomised controlled trial. Lancet
2016;387:2117–24.
10 Squires J, Twombly E, Bricker D, Potter L. Ages and Stages
Questionnaires – Third Edition. ASQ-3 User’s Guide. Baltimore, MD:
Brookes; 2009.
11 Steenis LJP, Verhoeven M, Hessen DJ, van Baar AL. Parental and
professional assessment of early child development: the ASQ-3 and
the Bayley-III-NL. Early Hum Dev 2015;91:217–25.
12 Gioia GA, Espy KA, Isquith PK. Behavior Rating Inventory of
Executive Function – Preschool Version. Odessa, FL: Psychological
Assessment Resources.
13 van der Heijden KB, Suurland J, De Sonneville LMJ, Swaab HJT.
BRIEF-P Vragenlijst executieve functies voor 2-tot 5-jarigen.
Amsterdam: Hogrefe Uitgevers; 2013.
14 Achenbach TM, Rescorla LA. Manual for the ASEBA Preschool Forms
& Profiles. Burlington, VT: University of Vermont, Research Center
for Children, Youth, & Families.
15 Rescorla LA. Assessment of young children using the Achenbach
System of Empirically Based Assessment (ASEBA). Ment Retard Dev
Disabil Res Rev 2005;11:226–37.
16 Gates S, Brocklehurst P. How should randomised trials including
multiple pregnancies be analysed? BJOG 2004;111:213–9.
17 Yelland LN, Schuit E, Zamora J, Middleton PF, Lim AC, Nassar AH,
et al. Correlation between neonatal outcomes of twins depends on
the outcome: secondary analysis of twelve randomised controlled
trials. BJOG 2018;125:1406–13.
1136 ª 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists
van Winden et al.
18 Geraci M. Linear quantile mixed models: The lqmm package for
Laplace quantile regression. J Stat Softw 57:1–29.
19 Moher D, Schulz KF, Altman DG. The CONSORT statement: revised
recommendations for improving the quality of reports of parallel
group randomized trials. BMC Med Res Methodol 2001;1:2.
20 Klumper J, Kaandorp JJ, Schuit E, Groenendaal F, Koopman-
Esseboom C, Mulder EJH, et al. Behavioral and neurodevelopmental
outcome of children after maternal allopurinol administration during
suspected fetal hypoxia: 5-year follow up of the ALLO-trial. PLoS
One 2018;13:e0201063.
21 Wekker V, Karsten MDA, Painter RC, van de Beek C, Groen H, Mol
BWJ, et al. A lifestyle intervention improves sexual function of
women with obesity and infertility: a 5 year follow-up of a RCT.
PLoS One 2018;13:e0205934.
22 Nilsen RM, Vollset SE, Gjessing HK, Skjaerven R, Melve KK, Schreuder
P, et al. Self-selection and bias in a large prospective pregnancy cohort
in Norway. Paediatr Perinat Epidemiol 2009;23:597–608.
23 Teune MJ, van Wassenaer AG, Malin GL, Asztalos E, Alfirevic Z, Mol
BWJ, et al. Long-term child follow-up after large obstetric randomised
controlled trials for the evaluation of perinatal interventions: a
systematic review of the literature. BJOG 2013;120:15–22.
24 Sribnick EA, Del Re AM, Ray SK, Woodward JJ, Banik NL. Estrogen
attenuates glutamate-induced cell death by inhibiting Ca2+ influx
through L-type voltage-gated Ca2+ channels. Brain Res
2009;18:159–70.
25 Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental
passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol
1995;172:1304–6.
1137ª 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists
Impact of nifedipine and atosiban on child outcome
